SCHEMBL3488933

SCHEMBL3488933

Cc1cc(F)cc(Oc2ccc(N)c(N(C)C(=O)O)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PPARG P37231 1/20 0.37
HSD17B1 P14061 2/20 0.36
HSD17B2 P37059 2/20 0.36
GCK P35557 2/20 0.35
VEGFA P15692 1/20 0.34
BRAF P15056 1/20 0.34
HDAC1 Q13547 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
NR4A1 P22736 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
MAPT P10636 1/20 0.32
POLB P06746 1/20 0.31
KEAP1 Q14145 1/20 0.31
BCHE P06276 2/20 0.31
ACHE P22303 2/20 0.31
FPR2 P25090 1/20 0.31
SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488271 0.92 VEGFA (0.40) PPARGGCKVEGFABRAFHDAC1
SCHEMBL3488408 0.88 SMN1; SMN2 (0.35) SMN1; SMN2HSD17B1HSD17B2GCKVEGFA
SCHEMBL3488382 0.86 EPAS1 (0.41) PPARGVEGFASCN9A
SCHEMBL3489386 0.86 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HSD17B1HSD17B2BRAF
SCHEMBL3488333 0.85 BRAF (0.44) ALDH1A1GCKBRAFHDAC1MEN1
SCHEMBL27782502 0.85 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2PPARGHSD17B1HSD17B2
SCHEMBL3488177 0.84 HSD17B1 (0.44) ALDH1A1SMN1; SMN2HSD17B1HSD17B2BRAF
SCHEMBL3487215 0.83 HSD17B1 (0.52) ALDH1A1SMN1; SMN2HSD17B1HSD17B2MEN1
SCHEMBL3487710 0.82 MRGPRX4 (0.38) PPARGHSD17B1HSD17B2GCKBRAF
SCHEMBL3487567 0.82 CHEK2 (0.39) PPARGHSD17B1HSD17B2GCKBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA ALDH1A1 698/4885SMN1; SMN2 4397/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.